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Introduction
One may wonder what a biologist working in preclinical devel-
opment in a pharmaceutical industry—which does not develop
antimicrobials—can offer to the readers of a microbiology
journal. This is what I also wondered when I started writing
this article for International Microbiology. Although I received
a Ph.D. in microbiology twenty years ago, currently, the only
close relationship my work has with microbiology is through
the use of bacterial assays for genotoxicity testing in the differ-
ent phases of drug development (lead optimization and regula-
tory preclinical development). These tests, including the SOS
chromotest, the Umu test (both carried out in Escherichia
coli), and any of the different versions of the Ames test (all of
them using different strains of Salmonella typhimurium), are
well known to microbiologists and other scientists involved in
assessments of genotoxic potential. As a final user of these
models, I do not think that I could offer interesting findings,
other than rates of positives/negatives or correlations with
other assays for genotoxicity or with carcinogenicity. In fact,
these models are so widely used that I do not consider them to
be an important issue in the field of microbiology. These
assays, however, and especially the Ames test, are of great rel-
evance to one of the most controversial issues in Europe, the
new chemicals policy of the European Union.
European Commission proposal for
REACH (Registration, Evaluation and
Authorisation of Chemicals)
On October 29, 2003, the European Commission adopted a
proposal for a new EU regulatory framework for chemicals,
following The White Paper issued on February 27, 2001, on
a strategy for a future chemicals policy. Under the proposed
new system, called REACH (Registration, Evaluation and
Authorisation of Chemicals [1]), enterprises that manufac-
ture or import more than one tonne of a chemical substance
per year would be required to register these activities in a
central database. The aims of the proposed new regulation are
to improve protection of human health and the environment
while maintaining competitiveness and enhancing the inno-
vative capability of the EU chemicals industry. Furthermore,
REACH would give greater responsibility to industry to man-
age the risks from chemicals and to provide safety informa-
tion on the substances. This information would be passed
down the chain of production. Although some discrepancies
occur, it can be said that REACH represents some form of
consensus, as parties potentially affected by the new regula-
tion were consulted previously. This has allowed the
Commission to propose a streamlined, cost-effective system,
and the proposal is now under examination by the European
Parliament and the EU’s Council of Ministers for adoption
under the so-called co-decision procedure. However, the most
difficult aspect of REACH is predicting its acceptance, since,
according to the EU, REACH will increase competitiveness,
whilst the different industrial associations (CEFIC-European
Chemical Industry Council, EMCEF-European Mine,
Chemical and Energy Workers Federation, and ECEG,
European Chemical Employers Council) maintain that
competitiveness will be reduced [www.cefic.be/Files
/NewsReleases/Press%20 release_021203.pdf]. In particular,
SMEs (Small or Medium-Sized Enterprises) are concerned
about the possible economic consequences that REACH may
have on their operations, and the potential difficulties associ-
ated with the increase in costs.
The new regulation specified by REACH includes both
new and existing chemicals. “Existing chemicals” refers to
those marketed before September 1981, which represent
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more than 100,000 compounds (96% of the total), whereas
“new chemicals” are those marketed after September 1981,
translating into 3600 notifications (a 2003 figure). Although
“new chemicals” have been annotated with respect to an ade-
quate testing strategy following the different international
guidelines, for “existing chemicals” the available information
is rather limited. In fact, it is difficult for citizens to even
know which chemicals are “new” and which are “existing”,
neither do they know whether data on the safety of “existing
chemicals” are available.
The cost of safety
The cost of applying REACH to existing chemicals would be,
according to DG Enterprises, around 2.3 billion Euros, as
reported by Dr. Egbert Holthuis [2,3]. Other evaluations
result in much higher figures, with costs as high as 9000 mil-
lion Euros and, until 2048, potentially involving the use of
around 13 million vertebrates (worst-case scenario) [4]. More
recent evaluations result in slightly lower figures. Note that,
in 1999, around 10 million animals per year were used to
cover the testing needs in the 15 member states comprising
the EU at that time (Table 1). The testing schedule depends
on the number of tonnes of each chemical produced per year:
For chemicals produced in amounts of 1000 tonnes and more
per year, safety data (genetic toxicology. Animal toxicology,
ecotoxicology, etc.) should be available in 2018; six years
later for compounds produced in amounts between 100 and
1000 tonnes; and until 2048 for compounds produced in
amounts between 1 and 100 tonnes per year. The same eval-
uation states that the available European CROs (Contract
Research Organizations) will be unable to meet this time
frame if the testing of new chemicals, pharmaceuticals, cos-
metics, etc., is also taken into account. In any case, whatever
the scenario, the cost is very high, both in terms of money
and, more importantly, in terms of the number of vertebrates
that will be needed for testing.
Protecting people and preserving the environment in
order leave a better world for our children and for our chil-
dren’s children is a goal that is no doubt shared by everyone.
Surely no one would reject the idea that the world is threat-
ened by the abuse, both actual and potential, of chemicals and
their improper disposal, and that this problem must be
addressed in order to ensure protection of the planet. At the
same time, Europe has a commitment to reduce the number
of animals used in research: The 7th Amendment to the
Cosmetics Directive is a good start, since it bans the use of
animal assays for the testing of cosmetics. However, Table 1
shows that the situation is far from being perfect—first of all,
because animals used in cosmetic testing amount to less than
1 % of the almost 10 million animals used annually in various
kinds of research and testing The chemical industry, including
the production of household chemicals, uses only 12%, where-
as 55% are used in medical research, one third of these for
quality control of biologicals; only 10% of research animals
are used in toxicology-safety assessments (Fig. 1). Thus, the
ban in the cosmetics industry will not significantly reduce the
current use of laboratory animals. Moreover, the impact on the
use of transgenic strains in research as well as on animals used
to prepare in vitro models remains to be determined.
Alternatives to the use of animals 
in safety tests
Currently, only three methods, substitutes for skin corrosion,
hematotoxicity, and embryotoxicity, are considered as vali-
dated alternatives to animal testing and have been integrated
into international guidelines. In addition, the animal acute
lethal toxicity test has been further refined such that the num-
ber of animals required to conduct the test has been reduced.
Nonetheless, the situation is very poor with respect to exist-
ing alternatives and is only very slowly improving, since very
high-quality performances for the new testing approaches are
required, much higher than those of the current animal mod-
els, which have never been correctly validated. Thus, a very
interesting conflict arises: the increase in the number of ani-
mals needed to respond to REACH requirements (up to sev-
eral millions!) versus the implementation of the 3Rs: the
replacement refinement, and reduction of the use of animals
in scientific research. The affected industries are obviously
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Table 1. Groups of animals used in experimentation per year*
Animal group Percentage
Prosimians/monkeys/apes 0.1
Carnivores 0.4
Artio-/perissodactyla 1.3
Rabbits 2.3
Rats 26.6
Mice 54.0
Guinea pigs 3.0
Other rodents 1.0
Other mammals 0.1
Birds 4.7
Cold-blooded animals 6.6
*Data from the 3rd Commission Report on the number of animals used in
the EU, 1999, released in 2003 (9,814,171 animals used).
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concerned about this situation, not only due to the costs asso-
ciated with additional testing and the potential reduction in
competitiveness, but also, and mainly, to the absence of vali-
dated alternatives to animal experimentation. In fact,
although some assays have been accepted and entered into
international guidelines, there is the feeling, among industri-
al researchers, that regulators and evaluators have difficulties
in accepting these alternatives (and this taking into account
that industries perform a great part of their research activities
using in vitro methods). This situation is easily understand-
able since evaluators base their decisions on comparisons
with existing data. Under these circumstances, it is difficult
to decide whether a tested chemical is better or safer than a
compound analyzed earlier by a different method. Thus, new
testing approaches pose difficulties, regardless of the willing-
ness to find alternatives to animal experimentation.
Prospects for European industries
Another major difficulty of REACH is the implications for
large industrial groups versus SMEs. The latter claims that
they would not be able to protect themselves against the
potential of having to cease production of existing or new
chemicals, in case the testing approach decided upon in order
to comply with REACH regulations involved the use of not
sufficiently validated predictive assays. To address such con-
cerns, the IVTIP, the In Vitro Testing Industrial Platform
[www.ivtip.org], was established by companies involved in
the cosmetic, pharmaceutical, biotechnology, and chemical
industries, as well as Contract Research Organizations. Its
tasks include acting as a mediator between industry and EU
administrators and regulators. IVTIP members meet twice a
year for very informal discussions, to which both academic
researchers in the field of in vitro testing and representatives
from European institutions are invited. These meetings pro-
vide a good opportunity to promote multidirectional connec-
tions between industry, academics, and EU authorities,
always with the aim of improving the competitiveness of
European industries.
IVTIP also follows up on all European projects financed
by the European Commission dealing with in vitro testing
strategies, and presenting high degrees of applicability.
Curiously, in the last four years, the only microbiology proj-
ect addressing alternatives to animal testing that has been
monitored by the IVTIP is the research of Prof. Hella
Lichtenberg (University of Bonn), on the use of Saccharo-
myces cerevisiae as an alternative to the Ames test.
The potential of microbiology 
in safety assessment
It is likely that the interests of microbiologists and other sci-
entists using microbes in their work are very different from
those of scientists involved in safety assessment. However,
accepting that I am outdated in the field of microbiology,
there are two aspects, one that might have an enormous
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Fig. 1. Objective regarding the annual use of research animals. 3rd Commission Report on the Number of Animals Used in
the EU, 1999 (9,814,171 animals used).
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impact on safety assessment in general and the other on the
testing requirements related to REACH in particular, in
which I think microbiologists have a role to play. First of all,
the question of mitochondria. Any toxicologist would agree
that, while the molecular mechanisms might be very differ-
ent, mitochondrial abnormalities are frequently observed as
part of the response to many toxic chemicals. Moreover, there
is a great interest in finding test models that could predict
mitochondrial dysfunction. As it is widely accepted that bac-
teria are related to the parasitic precursors that evolved into
mitochondria, they may offer a model system for screening
chemicals potentially toxic to those organelles. The second
aspect has to do with membranes. Some toxic reactions, such
as corrosion and irritation, have important physicochemical
effects on skin and mucosa. Unfortunately, the cell wall and
membranes of bacteria have a composition different from
human (or eukaryotic) cell membranes. However, microbiol-
ogists have long been able to obtain bacteria free of their
outer wall. Thus, it is easy to imagine a very inexpensive, fast
test for corrosion and irritation based on the disruption of
bacterial membranes, as determined by changes in
absorbance. Just imagine how long it would take and the rel-
ative low cost of testing the 100,000 existing chemicals with
such a system.
Microbial methods in safety assessment are being used,
mainly for genotoxicity assessment but also in the early phas-
es of screening, Some of these methods, including Ames II,
SOS chromotest, and Umu test, have been modified to adapt
to high-throughput screening requirements. This is not only
because they are inexpensive, but also because they are
robust and produce clear-cut responses that are easy to inter-
pret by both researchers and governmental policy makers.
Hopefully, this article will motivate microbiologists and
those scientists with related interests to develop additional
screening methods, so that their research activities play a
larger role in the arena of safety testing.
Concluding remarks
I cannot end this discussion without adding that any new test-
ing model with potential application for safety assessment
should quickly be submitted to pre-validation and validation
exercises. These involve establishing correlation models and
determining intra- and inter-laboratory consistency, and have
evolved with time in order to gain in efficiency and to reduce
the enormous costs and amount of time involved. Interested
researchers should contact the European Center for
Validation of Alternative Methods (ECVAM) at the EU Joint
Research Center in Italy [http://ecvam.jrc.it/index.htm],
which provides instructions on how to proceed and how to
find interested partners. Both ECVAM and IVTIP have been
involved in recent projects granted by the European
Commission whose final objective is to gain the status of pre-
validated alternative prior to entry into the formal validation
phase.
The final topic in this complex discussion is the impact
of such research activities. It is obvious that reduction,
replacement, and refinement in animal experimentation have
tremendous ethical and social impact. Advancements in
these areas will result in a better and more “humane” world.
Unfortunately, it seems that research activities focusing on
the 3Rs do not have sufficient scientific acceptance, as
determined by the number of journals publishing the related
results. It is somewhat surprising that the readership for a
paper explaining in detail the mechanism of action of a given
enzyme, using very new and sophisticated techniques, can
be much higher than that of a paper reporting on a simple
method that reduces animal testing, saves animal lives, and
reduces the cost of research, i.e., having a direct effect on the
quality of life. Perhaps even worse is that scientists not
directly involved in the field of alternatives do not consider
their results with respect to this very important and ethical
objective.
I hope that this discussion will awaken in its readers some
interest in the field of replacement, reduction and refinement,
and in a further understanding of the related molecular mech-
anisms that may foster their development. Finally, while new
in vitro screening methods for determining the safety of
existing chemicals, establishing exposure levels (either to
people or the environment), and labeling substances are
needed, the same argument can be made regarding new cos-
metics and chemicals. REACH, by forcing us to establish in
vitro approaches with broad regulatory acceptance for evalu-
ating the enormous amount of chemicals to be tested, now
and in the future, will greatly contribute to protecting both
humans and the world they live in.
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